There is more to this story than just making technology open to the public so others can manufacturer it. Think about what is being said here. The manufacture of face masks went overseas. When many were needed, foreign manufacture could not keep up and the prices were ridiculous. We are in a situation of whether we want all product being manufactured overseas and face shortages and high prices even though costs do not require such? Speaking of which EpiPens are another example here. Nobody could duplicate the delivery system EpiPen had. Mylan changed Pfizer’s EpiPen design to achieve patented exclusivity. Teva could not duplicate it as a generic because patients could not use the Mylan instructions in applying the Teva generic. According to FDA’a
Topics:
Bill Haskell considers the following as important: Healthcare, Patent Monopoly, politics, Taxes/regulation, US/Global Economics
This could be interesting, too:
Peter Radford writes Election: Take Four
Joel Eissenberg writes Diversity in healthcare delivery
Angry Bear writes Heathcare Insurance Companies Abandoning Medicare Advantage
Joel Eissenberg writes Access to medical care: right or privilege?
There is more to this story than just making technology open to the public so others can manufacturer it. Think about what is being said here. The manufacture of face masks went overseas. When many were needed, foreign manufacture could not keep up and the prices were ridiculous. We are in a situation of whether we want all product being manufactured overseas and face shortages and high prices even though costs do not require such?
Speaking of which EpiPens are another example here. Nobody could duplicate the delivery system EpiPen had. Mylan changed Pfizer’s EpiPen design to achieve patented exclusivity. Teva could not duplicate it as a generic because patients could not use the Mylan instructions in applying the Teva generic. According to FDA’a rules, the Teva product could not be cast as a generic for the Mylan EpiPen in the marketplace as it could “not” be used in the same manner. Ridiculous rule right? The bigger issue was the damn pen had ~$10 of parts in it. You needed two pens at $600/pair for ~$60 worth of meds and materials. That is a good argument for what Dean is talking about, but, what could improve delivery change?
Vimovo consists of two common drugs, Aleve and Nexium. Vimovo goes for $3000. Prescriptions of Aleve and Nexium for $40.
Simpler example is Coricidin HBP. You can buy 20 Tabs for about $8.00. Two tabs every 4 – 6 hours for a cold. Maybe a two day supply for a cold. Or you can buy 325mg tabs of generic tylenol 100 tabs for $5 and 100 tabs of 4mg Chlorpheniramine maleate for approximately $5. Two generic tylenol and one tab Chlorpheniramine maleate equals two Corcidin tabs. 50 Day supply of cold remedy. The Chlorpheniramine maleate is great for sinus issues.
But the real issue with pharma is the distribution system. You have the manufacturer who sets the price. PBMs working with the drug stores, the manufacturers, and the insurance companies. Whether your drug becomes a tier one, two, or 3, etc, depends on those PBMs. Then there are the main distributors AmerisourceBergen Drug Co., Cardinal Health Inc. and McKesson Corp.
A federal judge ruled in favor of three major U.S. drug distributors (guess who?) in a landmark lawsuit that accused them of causing a health crisis by distributing 81 million pills over eight years in one West Virginia County and the small city of Huntington which were ravaged by opioid addiction. There are no cities in West Virginia with over 100,000 people.
The Williamson, West .Virginia. story of being the recipient of ~21 million hydrocodone and oxycodone pills to two small pharmacies. Williamson had a population of 3000 during the period from 2008 and 2015. 7200 pills for each citizen there. One a day for many years to come then.
Pharmaceutical issues in costs and prices go well beyond the manufacturers. I would suggest you read Andrew Feins Drug Channels. Latest topic is interesting:
“This month, nine biosimilar versions of adalimumab launched in the U.S. market. As I predicted in 2021, some products launched with list prices that are only slightly lower than Humira’s list price, while others are trying to tempt payers and pharmacy benefit manages (PBMs) with deep list price discounts.
Surprisingly, two PBMs—Express Scripts and OptumRx—will each offer at least one low-list-price biosimilar option on their main national formularies.”
This is a good example of what we are up against. It is more than drug development.
Dean Baker’s piece on Alternatives to Patent Monopolies . .
Government to Consider Alternatives to Patent Monopoly Financing of Drug Development, Center for Economic and Policy Research, cepr.net, Dean Baker
In some really big news likely to get almost no media attention, the chair of the Senate HELP Committee, Senator Bernie Sanders negotiated a deal with Bill Cassidy. Bill is the ranking Republican, on a package of amendments to the reauthorization of the nation’s pandemic preparedness law. While there are a number of items in the deal, a really big one is funding for a study to be done by the National Academies of Sciences, Engineering, and Medicine (NASEM) to consider alternatives to patent monopoly financing of the development of prescription drugs.
This is “potentially huge,” since our current system is a disaster. No one ever said it was a great idea to finance research by charging tens of thousands of dollars for life-saving drugs, when these drugs would sell for a few hundred dollars in a free market without patent protection. We just ended up here. The study outlined in this bill should mean we will get a serious evaluation of the current route for financing research relative to alternatives.
As I have argued endlessly, the current patent monopoly system is just an incredibly bad way to finance the development of new drugs, vaccines, and other health related products. There are many different reasons for this view.
Lower prices
Without patent monopolies and related protections, such as test data exclusivity or non-disclosure agreements, drugs would almost invariably be cheap. It is rare for a drug to be expensive to manufacture and distribute. In this free market world, most drugs would sell for a few dollars a prescription, or in some cases, ten or twenty dollars. We would not have drugs selling for hundreds or even thousands of dollars per prescription.
Most people have some type of insurance, either from the government or private insurance, which picks up much of the tab for drugs. Even if this may make the price affordable for patients, this is not the end of the story.
Insurers are not happy about paying hundreds of dollars for a prescription. When a patient is prescribed an expensive drug, insurers will typically make patients jump through hoops, like getting special letters from their doctor, or first trying a cheaper alternative. These bureaucratic hoops would be an annoyance for anyone, but they are especially bad in this context.
The people who need expensive drugs are often in poor health. That is why they need expensive drugs. So, we end up forcing people in bad health to spend their time chasing after doctors or other health care professionals, to get insurers to pay for a drug that would be cheap in a free market. That doesn’t make a lot of sense. Needless to say, many people don’t follow through with the necessary steps and end up not getting the drug their doctor prescribed.
Ending Corruption
Everyone who took Econ 101 can tell you how a 10 or 25 percent trade tariff leads to corruption. People play games mis-categorizing products to find ways around the tariff. The beneficiaries of the tariff use campaign contributions, and occasionally outright bribes, to get politicians to extend and expand the tariff.
These sorts of corruption are completely predictable outcomes from trade tariffs, and we routinely see them in the world. Patent monopolies on drugs raise the same sort of problems, but instead of a tariff that might raise the price of a product by 10-25 percent, we’re talking about raising the price of drugs by many thousand percent with patent monopolies.
The potential profits from selling a drug at a price that is several thousand percent above its production cost gives a very big incentive for corruption. Most immediately the corruption takes the form of misleading doctors and the public about the safety and effectiveness of a product.
This effort takes a variety of forms. The most visible are the endless television ads telling us about the merits of various drugs for treating arthritis, diabetes, or various other conditions. While these ads can provide some information, hearing a famous actor touting a drug they were paid to promote is probably not a good way to determine the best course of treatment for a medical condition.
In fact, this sort of direct to the patient advertising had been banned for many decades, until the Supreme Court determined that this restriction violated free speech. Whether or not the Court’s decision was correct, it would become moot if we took away the patent monopolies. No one would be spending billions of dollars on ads pushing prescription drugs if they were sold in a free market like shovels and paper clips.
But this is only the beginning of the corruption story. Drug companies routinely pay doctors to promote their drugs through various channels. While there have been efforts in recent decades to crack down on the practice of having professional medical opinions for hire, medical journals still struggle to ensure that published articles were actually written by the named authors and were not paid for by drug companies. Researchers who get generous consulting fees from drug companies may be reluctant to criticize a drug marketed by that company, for fear of having this income stream cut off.
This is an especially big issue in health care, as opposed to other areas where companies push their products. This is partly because there are serious problems of asymmetric information; the drug companies know more about their drugs than patients or their doctors. And, also because the consequences are so huge. People may be unhappy if their latest smartphone didn’t live up to expectations, but this just means they wasted some money. If they take a heart medication that is ineffective, or possibly even harmful, it can seriously damage their health or even cost them their life.
The real dangers from mismarketing drugs are not hard to find. To take a couple of examples, the pharmaceutical giant Merck paid billions of dollars to settle suits alleging that it concealed evidence that its arthritis drug, Vioxx, posed serious dangers to people with heart conditions. The opioid crisis stemmed in large part from drug companies misleading doctors about the extent to which the new generation of opioids was addictive. More recently, Biogen lobbied the FDA to get it to approve its Alzheimer drug Adulhem, even though its expert panel felt that it was ineffective and potentially dangerous.
Some mistakes in research are inevitable, but the incentive to deliberately mislead doctors and the public about the safety and effectiveness of drugs will largely disappear without patent monopolies. This would be a huge victory for public health.
Ending Waste in the Patent System Itself
The costs of maintaining and enforcing the patent system are a large deadweight loss from the standpoint of the economy as whole. The resources devoted to filing and enforcing patents do not add even a minute to anyone’s life or improve its quality in any way. The time of the people involved in this process could instead be employed in something productive.
This is getting to be a bigger deal over time. It is increasingly common for drug companies to file dozens of patents of dubious quality to extend the period of protection for their blockbuster drugs. This is a practice that can pay off big for the drug company, even if it is an incredible waste for society.
Patent monopolies are supposed to be an incentive for innovation, but a dubious patent, claiming a monopoly on a trivial innovation, is simply a way to block competition. Drug companies can benefit from this process because of the incredible asymmetry involved in any potential legal dispute. A drug company protecting its patent is fighting for the ability to continue to sell their drug at the patent monopoly protected price. A generic company challenging the patent is seeking the right to sell the drug in a competitive market.
In addition to possibly securing a monopoly for longer time than is warranted, millions of dollars of legal expenses can be incurred in these battles. These cases also present another opportunity for corruption, with drug companies sometimes making what are effectively payoffs, in the form of licensing agreements, to persuade generic manufacturers to drop lawsuits contesting patents.
Greater Progress with Open Research
The patent monopoly financing system encourages secrecy in research. Pfizer and Merck want to get as much as possible out of their research and avoid giving away information that could provide an advantage to competitors. This means they only disclose information that is necessary to get a patent. They will not publish research findings that could be useful to competitors. Also, their clinical trial results are proprietary, although in response to pressure, drug companies have been much better about making their full results available in recent years.
If we paid for research upfront, it could be a requirement that all findings be posted on the web as soon as practical. All patents would be in the public domain and any non-disclosure agreements on the research would not be enforceable.[1]
If this sort of system had been in place during the pandemic it would have meant that all the research being done on tests, treatments, and vaccines, everywhere in the world, would have been freely shared. This meant that anyone with the manufacturing capacity could have begun making not only the mRNA vaccines, but also the AstraZeneca vaccine, as well as the ones developed by China, India, and Cuba. The manufacturing could have been done even in advance of approval, since the benefits of having tens of millions of vaccines quickly available swamps the risk of having to throw them out if they don’t prove safe and effective. This would have allowed the world to get vaccinated far more quickly, slowing the spread of the pandemic. It quite likely would have prevented the development of the omicron strain and possible even the delta strain, saving millions of lives and avoiding hundreds of millions of infections.
It is true that this would have required some sort of international agreement on sharing technology, but the patent system also requires agreement on rules and enforcement. And, anyone who has followed recent trade negotiations knows these agreements have not been easy to reach.
Fostering Research Beyond Patentable Products
When we are relying on patent monopolies to finance research, the only avenues that companies will pursue are ones that are likely to lead to a patentable product. If it seems that diet, exercise, or environmental factors might be important for addressing a specific condition, companies will have no incentive to pursue these paths.
In principle, we have the National Institutes of Health and other public agencies that can pursue these avenues, but there is no reason to assume that information will be freely transferred. After all, if a drug company has spent years researching a drug for a diabetes, and it uncovers evidence that dietary issues can be very important in treatment, it has little incentive to share information that could undermine the market for its drug.
By contrast, if all research was fully open, and drug companies are being rewarded for doing research that advances public health, they would have every reason in the world to share findings that were not related to a patentable product. It is also worth noting that this problem also applies to researching new uses for old drugs. If a drug that is off-patent proves to be effective in treating a different condition than the one for which it had been approved, a company would have little incentive to pursue this research.
Inequality
People in policy debates like to blame the rise in inequality over the last four decades on technology. This is not true. It is our rules on technology, not the technology itself, that has led to the growth in inequality.
The case of the Moderna Covid vaccine provides a great case study to make this point. The government paid Moderna just under $1 billion to develop and test its vaccine. Rather than insisting that the vaccine be placed in the public domain, so that it could be produced as a cheap generic, we allowed Moderna to maintain control over its production and distribution. As a result we created at least five Moderna billionaires by the summer of 2021.
There was nothing about the technology that required that a small number of people at Moderna would get incredibly rich. The problem was the rules we put in place for controlling the technology.
This issue applies to the patent monopoly system more broadly. If we had a system where drug companies contracted with the government to do research, there would undoubtedly be talented and hardworking researchers who would get substantial rewards. However, it is unlikely that this system would produce many billionaires.
Enormous Amount of Money
And, we should all recognize that there is an enormous amount of money at stake. We will spend over $550 billion this year on prescription drugs. These drugs would likely cost less than $100 billion in a free market without patents and other protections. The difference of $450 billion (more than $5 trillion over a decade) comes to more than $3,000 a year per family. It is real money and it make a really big difference whose pockets it ends up in.
The issue of inequality should not be a primary factor in designing the best mechanism for developing new drugs, however it is reasonable to consider the impact that the system has on inequality. It is more than a bit backward to design a system that produces an enormous amount of inequality and then to complain about inequality. It is much easier to avoid creating massive inequality in the first place, than to structure the system in a way that generates inequality and somehow expect to be able to tax it back.
As should be clear to everyone by now, money creates political power. If we allow people to get very rich, they will use their political power to ensure they stay rich.